Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Hans Tesch

Showing results (121-130 of 171) with videos related to

Pageof 18
Sort By:
Geburtshilfe Und Frauenheilkunde|September 16, 2022
Update Breast Cancer 2022 Part 4 - Advanced-Stage Breast CancerBahriye Aktas, Tanja N Fehm, Manfred Welslau, et al.
JAMA Oncology|March 13, 2020
Association of Germline Variant Status With Therapy Response in High-risk Early-Stage Breast Cancer: A Secondary Analysis of the GeparOcto Randomized Clinical TrialEsther Pohl-Rescigno, Jan Hauke, Sibylle Loibl, et al.
Geburtshilfe Und Frauenheilkunde|March 13, 2023
Update Breast Cancer 2022 Part 5 - Early Stage Breast CancerTanja N Fehm, Manfred Welslau, Volkmar Müller, et al.
Breast Cancer Research : BCR|October 24, 2020
Gemcitabine as adjuvant chemotherapy in patients with high-risk early breast cancer-results from the randomized phase III SUCCESS-A trialAmelie de Gregorio, Lothar Häberle, Peter A Fasching, et al.
Breast (Edinburgh, Scotland)|December 15, 2017
Impact of disease progression on health-related quality of life in patients with metastatic breast cancer in the PRAEGNANT breast cancer registryVolkmar Müller, Naiba Nabieva, Lothar Häberle, et al.
The Lancet. Oncology|May 6, 2014
Neoadjuvant carboplatin in patients with triple-negative and HER2-positive early breast cancer (GeparSixto; GBG 66): a randomised phase 2 trialGunter von Minckwitz, Andreas Schneeweiss, Sibylle Loibl, et al.
Geburtshilfe Und Frauenheilkunde|July 29, 2022
Update Breast Cancer 2022 Part 2 - Advanced Stage Breast CancerVolkmar Müller, Manfred Welslau, Diana Lüftner, et al.
BMC Cancer|November 12, 2020
Heregulin (HRG) assessment for clinical trial eligibility testing in a molecular registry (PRAEGNANT) in GermanyHanna Huebner, Christian M Kurbacher, Geoffrey Kuesters, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 24, 2018
BRCA1/2 Mutations and Bevacizumab in the Neoadjuvant Treatment of Breast Cancer: Response and Prognosis Results in Patients With Triple-Negative Breast Cancer From the GeparQuinto StudyPeter A Fasching, Sibylle Loibl, Chunling Hu, et al.
Geburtshilfe Und Frauenheilkunde|July 29, 2022
Update Breast Cancer 2022 Part 1 - Early Stage Breast CancerManfred Welslau, Volkmar Müller, Diana Lüftner, et al.
Pageof 18

Showing results (121-130 of 171) with videos related to

Sort By:
Pageof 18
Geburtshilfe Und Frauenheilkunde|September 16, 2022
Update Breast Cancer 2022 Part 4 - Advanced-Stage Breast CancerBahriye Aktas, Tanja N Fehm, Manfred Welslau, et al.
JAMA Oncology|March 13, 2020
Association of Germline Variant Status With Therapy Response in High-risk Early-Stage Breast Cancer: A Secondary Analysis of the GeparOcto Randomized Clinical TrialEsther Pohl-Rescigno, Jan Hauke, Sibylle Loibl, et al.
Geburtshilfe Und Frauenheilkunde|March 13, 2023
Update Breast Cancer 2022 Part 5 - Early Stage Breast CancerTanja N Fehm, Manfred Welslau, Volkmar Müller, et al.
Breast Cancer Research : BCR|October 24, 2020
Gemcitabine as adjuvant chemotherapy in patients with high-risk early breast cancer-results from the randomized phase III SUCCESS-A trialAmelie de Gregorio, Lothar Häberle, Peter A Fasching, et al.
Breast (Edinburgh, Scotland)|December 15, 2017
Impact of disease progression on health-related quality of life in patients with metastatic breast cancer in the PRAEGNANT breast cancer registryVolkmar Müller, Naiba Nabieva, Lothar Häberle, et al.
The Lancet. Oncology|May 6, 2014
Neoadjuvant carboplatin in patients with triple-negative and HER2-positive early breast cancer (GeparSixto; GBG 66): a randomised phase 2 trialGunter von Minckwitz, Andreas Schneeweiss, Sibylle Loibl, et al.
Geburtshilfe Und Frauenheilkunde|July 29, 2022
Update Breast Cancer 2022 Part 2 - Advanced Stage Breast CancerVolkmar Müller, Manfred Welslau, Diana Lüftner, et al.
BMC Cancer|November 12, 2020
Heregulin (HRG) assessment for clinical trial eligibility testing in a molecular registry (PRAEGNANT) in GermanyHanna Huebner, Christian M Kurbacher, Geoffrey Kuesters, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 24, 2018
BRCA1/2 Mutations and Bevacizumab in the Neoadjuvant Treatment of Breast Cancer: Response and Prognosis Results in Patients With Triple-Negative Breast Cancer From the GeparQuinto StudyPeter A Fasching, Sibylle Loibl, Chunling Hu, et al.
Geburtshilfe Und Frauenheilkunde|July 29, 2022
Update Breast Cancer 2022 Part 1 - Early Stage Breast CancerManfred Welslau, Volkmar Müller, Diana Lüftner, et al.
Pageof 18